Acrivon Therapeutics to presents data on deployment of AP3 platform

Acrivon Therapeutics announced the company will be presenting data on the ability of its AP3 platform to uniquely enable the clinical development of ACR-368 and the discovery and design of ACR-2316 at two upcoming scientific congresses: Human Proteome Organization World Congress taking place from October 20-24, 2024 in Dresden, Germany and EORTC-NCI-AACR Symposium taking place from October 23-25, 2024 in Barcelona, Spain. “We are excited to have these three presentations highlighting the unique and actionable capabilities of AP3 featured at two premier scientific conferences in Europe this month,” said Kristina Masson, Ph.D., M.B.A., co-founder and executive vice president of business operations at Acrivon and president and CEO of the company’s research subsidiary Acrivon AB in Lund, Sweden. “The presentations are the product of the efficient integration of our two teams of research scientists. In Lund, we utilize and leverage a world-class mass spectrometry and precision phosphoproteomics infrastructure. In Boston, we generate data and actionable insights through AP3 using state-of-the-art, fully scripted, algorithm-based, machine learning-enabled pathway and biomarker analyses. Our AP3 platform thus enables us to overcome many of the challenges facing the biopharma industry, including the discovery of clinical biomarkers, the identification of resistance mechanisms, indication finding, and prediction of patient responders. We have applied actionable insights from AP3 to the streamlined clinical development of ACR-368, and to rapidly design, discover and advance ACR-2316 into monotherapy clinical development in selected tumor types predicted sensitive with our AP3 platform. We firmly remain a science- and data-driven company, and it is always gratifying to be able to share our work at prestigious scientific conferences.”